Dexamfetamine is the dextro-isomer of racemic amphetamine, belonging to the phenethylamine class of centrally acting sympathomimetic agents. Chemically designated as $(2S)$<\/span>-1-phenylpropan-2-amine sulfate, it represents the pharmacologically active enantiomer of amphetamine. Under the Anatomical Therapeutic Chemical (ATC) system, dexamfetamine is indexed under N06BA02.<\/p>\n Product Context:<\/b> Formulated as immediate-release oral tablets (typically 5 mg) or oral liquid solutions. Unlike lisdexamfetamine (which is a prodrug), dexamfetamine is active immediately upon ingestion.<\/p>\n<\/li>\n Controlled Status:<\/b> Strictly regulated as a Prescription Only Medicine (POM) and a Schedule II Controlled Substance (or Class B \/ Schedule 2 Controlled Drug internationally) due to its high potential for abuse, psychological dependence, and misuse liability.<\/p>\n<\/li>\n<\/ul>\n Dexamfetamine exerts its therapeutic and stimulant effects by modulating central monoamine neurotransmission:<\/p>\n Presynaptic Release:<\/b> Enters presynaptic monoamine nerve terminals via active transport (DAT and NET), where it induces the robust, non-exocytotic release of dopamine (DA) and norepinephrine (NE) from storage vesicles into the cytoplasm and subsequently into the synaptic cleft.<\/p>\n<\/li>\n Reuptake Inhibition:<\/b> Binds to and inhibits monoamine transporters (DAT, NET, and to a lesser extent, SERT), preventing the clearance of neurotransmitters from the synapse.<\/p>\n<\/li>\n MAO Inhibition (Weak):<\/b> Weakly inhibits monoamine oxidase (MAO) enzymes at high concentrations.<\/p>\n<\/li>\n Pharmacodynamic Profile:<\/b> Amplified catecholamine signaling within the prefrontal cortex and striatum improves sustained attention, impulse control, motor hyperactivity, and wakefulness in narcolepsy.<\/p>\n<\/li>\n<\/ul>\n Licensing for dexamfetamine includes:<\/p>\n Attention Deficit Hyperactivity Disorder (ADHD):<\/b> Treatment of ADHD in children (aged 3 years and older) and adults as part of a comprehensive management program.<\/p>\n<\/li>\n Narcolepsy:<\/b> Management of excessive daytime sleepiness associated with narcolepsy.<\/p>\n<\/li>\n<\/ul>\n Dosing & Administration Regimen:<\/i><\/p>\n Individualized Titration:<\/b> Initiated at low doses (e.g., 5 mg once or twice daily) and titrated upward gradually by small increments at weekly intervals based on clinical response and tolerability.<\/p>\n<\/li>\n Timing of Doses:<\/b> Administered in divided doses throughout the day, with the first dose taken upon awakening. Subsequent doses are spaced at intervals of 4 to 6 hours. Avoid late afternoon or evening administration<\/b> to prevent severe, prolonged insomnia.<\/p>\n<\/li>\n<\/ul>\n Absorption:<\/b> Rapidly and completely absorbed from the gastrointestinal tract following oral ingestion. Peak plasma concentrations ($C_{max}$<\/span>) are achieved within 1 to 3 hours ($T_{max}$<\/span>) for immediate-release formulations.<\/p>\n<\/li>\n Distribution:<\/b> Readily crosses the blood-brain barrier and placenta; distributes extensively into body tissues. Plasma protein binding is low (~15% to 20%).<\/p>\n<\/li>\n Biotransformation:<\/b> Metabolized in the liver primarily via aromatic and aliphatic hydroxylation, $N$<\/span>-dealkylation, and deamination. Major pathways involve CYP2D6 to yield active and inactive hydroxylated metabolites (such as 4-hydroxyamphetamine and norephedrine).<\/p>\n<\/li>\n Elimination:<\/b> Excreted predominantly via the kidneys in urine as unchanged parent drug and metabolites. Urinary elimination is heavily dependent on urinary pH: acidic urine accelerates renal clearance, whereas alkaline urine prolongs the elimination half-life. The terminal elimination half-life averages 10 to 12 hours in adults.<\/p>\n<\/li>\n<\/ul>\n Dexamfetamine stimulates the sympathetic nervous system, increasing heart rate, elevating blood pressure, dilating pupils, and suppressing appetite.<\/p>\n Very Common ($\\ge 1\/10$<\/span>):<\/b> Decreased appetite, weight loss, insomnia, dry mouth, headache, emotional lability, tachycardia, abdominal pain.<\/p>\n<\/li>\n Common ($\\ge 1\/100$<\/span> to $<1\/10$<\/span>):<\/b> Palpitations, anxiety, restlessness, dizziness, tremor, dysgeusia, constipation, diarrhea, hyperhidrosis, bruxism, growth velocity suppression in pediatric patients.<\/p>\n<\/li>\n Uncommon ($\\ge 1\/1,000$<\/span> to $<1\/100$<\/span>):<\/b> Hypertension, vision blurred, rash, libido changes, psychomotor hyperactivity, depression.<\/p>\n<\/li>\n Rare \/ Severe (<1\/1,000):<\/b> Psychotic episodes, visual and tactile hallucinations, cardiomyopathy (with chronic high-dose misuse), seizures, cerebrovascular accidents, myocardial infarction, sudden cardiac death in vulnerable individuals.<\/p>\n<\/li>\n<\/ul>\n Known hypersensitivity to amphetamine products or formulation excipients.<\/p>\n<\/li>\n Concomitant use with Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of their cessation (risk of life-threatening hypertensive crisis).<\/p>\n<\/li>\n Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate-to-severe hypertension, or structural cardiac abnormalities.<\/p>\n<\/li>\n Hyperthyroidism, glaucoma, or history of advanced agitated states.<\/p>\n<\/li>\n History of active drug abuse or substance use disorder.<\/p>\n<\/li>\n<\/ul>\n Monoamine Oxidase Inhibitors (MAOIs):<\/b> Concurrent administration triggers severe hypertensive crises and dangerous hyperthermia.<\/p>\n<\/li>\n Serotonergic Agents (SSRIs, SNRIs):<\/b> Co-administration elevates the risk of serotonin syndrome due to enhanced monoaminergic activity.<\/p>\n<\/li>\n Acidifying & Alkalinizing Agents:<\/b> Gastrointestinal and urinary acidifiers (e.g., ascorbic acid, ammonium chloride) accelerate renal clearance and reduce efficacy, whereas urinary alkalinizers (e.g., sodium bicarbonate) prolong half-life and increase systemic exposure.<\/p>\n<\/li>\n Antihypertensives:<\/b> Stimulants can antagonize the blood pressure-lowering effects of antihypertensive medications.<\/p>\n<\/li>\n<\/ul>\n Boxed Warning (Abuse, Misuse, and Dependence):<\/b> CNS stimulants have a high potential for abuse and dependence. Assess clinical risk prior to prescribing and monitor patients regularly for signs of misuse, diversion, or dose escalation.<\/p>\n<\/li>\n Cardiovascular Evaluation:<\/b> Evaluate cardiac status prior to treatment. Monitor blood pressure and heart rate regularly during therapy, particularly in patients with underlying cardiovascular conditions.<\/p>\n<\/li>\n Growth Suppression:<\/b> Long-term stimulant use in pediatric patients can be associated with temporary suppression of weight gain and linear growth velocity; monitor height and weight periodically<\/p>\n<\/li>\n<\/ul>\n\n \n
2. Mechanism of Action and Pharmacodynamics<\/h2>\n
\n
3. Approved Clinical Indications and Dosing Scope<\/h2>\n
\n
\n
4. Pharmacokinetic Profile and Metabolic Fate<\/h2>\n
\n
5. Physiological Effects and Adverse Event Spectrum<\/h2>\n
Adverse Drug Reaction Spectrum<\/h3>\n
\n
6. Contraindications, Drug Interactions, and Clinical Precautions<\/h2>\n
Controindicazioni<\/h3>\n
\n
Key Drug Interactions<\/h3>\n
\n
Clinical Precautions and Monitoring<\/h3>\n
\n